Denosumab

Xgeva, Wyost, Jubbonti, Conexxence, Bomyntra, Stoboclo, Osenvelt, Bilprevda, Bildyos, Ospomyv, Enoby, Xtrenbo, Bosaya, Aukelso, Xbryk, Boncresa, Oziltus, Prolia

Uncategorized

Standard

Half-life

25-28 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Monoclonal antibody binding RANKL, preventing osteoclast formation and bone resorption

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Dense Breasts
·Osteoporosis
·Systemic Mastocytosis
·Melanoma Stage Iii
·Melanoma Stage Iv

Interactions

No curated interaction pairs are recorded for Denosumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Back pain
Extremity pain
Hypocalcemia
Musculoskeletal pain

Pharmacokinetics

Published parameters · PMID:22350564

Half-life: 25-28 days
Protein binding: N/A
Clearance: 0.004 L/h; adult osteoporosis patients
Volume of distribution: 3 L
Bioavailability: 62%
Renally eliminated: 0%
Model: 2-compartment

Pregnancy & lactation

Not recorded for Denosumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement